AMRI Signs Agreement with AstraZeneca for COVID-19 Vaccine Delivery

September 9, 2020

AMRI will provide AstraZeneca with manufacturing capacity and sterile fill/finish services at its drug product manufacturing facility in Albuquerque, NM.

AMRI, a provider of drug development and manufacturing solutions, announced on Sept. 3, 2020 that it signed a supply agreement with AstraZeneca to support the manufacture of AstraZeneca’s COVID-19 vaccine candidate, AZD1222.

According to an AMRI press release, AMRI will provide AstraZeneca with manufacturing capacity and sterile fill/finish services at its drug product manufacturing facility in Albuquerque, NM.

“AMRI is proud to partner with AstraZeneca in pursuit of a vaccine that could protect people against the coronavirus pandemic,” said John Ratliff, CEO, AMRI, in the press release. “Our experience in drug product fill/finish will enable timely manufacturing to make the vaccine available as soon as possible to advance bringing life-changing medicines to market.”

On Sept. 9, 2020, AstraZeneca announced that all ongoing randomized, controlled clinical trials involving AZD1222 will temporarily pause due to a patient’s unexplained illness in the vaccine’s Phase III trial in the United Kingdom, an AstraZeneca press release said. Currently, AstraZeneca is independently reviewing the incident.

Sources: AMRI, AstraZeneca